Literature DB >> 27493891

Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response.

M Kudo1.   

Abstract

Entities:  

Year:  2016        PMID： 27493891      PMCID： PMC4960361          DOI： 10.1159/000443563

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  23 in total

1.  Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.

Authors:  Akiko Makiyama; Yoshito Itoh; Akinori Kasahara; Yasuharu Imai; Sumio Kawata; Kentaro Yoshioka; Hirohito Tsubouchi; Kendo Kiyosawa; Shinichi Kakumu; Kiwamu Okita; Norio Hayashi; Takeshi Okanoue
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

2.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

Authors:  A Kasahara; N Hayashi; K Mochizuki; M Takayanagi; K Yoshioka; S Kakumu; A Iijima; A Urushihara; K Kiyosawa; M Okuda; K Hino; K Okita
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

3.  Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan.

Authors:  Akira Sato; Michio Sata; Kenji Ikeda; Takashi Kumada; Namiki Izumi; Yasuhiro Asahina; Yukio Osaki; Kazuaki Chayama; Shuichi Kaneko; Akito Sakai; Morikazu Onji; Yoichi Hiasa; Takumi Omura; Itaru Ozeki; Osamu Yokosuka; Shuichiro Shiina; Mariko Itsubo; Shuhei Nishiguchi; Katsuharu Hirano; Tatsuya Ide; Shotaro Sakisaka; Takahiro Yamasaki; Isao Hidaka; Masatoshi Tanaka; Soo Ryang Kim; Takafumi Ichida
Journal:  Intern Med       Date:  2013       Impact factor: 1.271

4.  Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.

Authors:  Yasuhiro Asahina; Kaoru Tsuchiya; Nobuharu Tamaki; Itsuko Hirayama; Tomohiro Tanaka; Mitsuaki Sato; Yutaka Yasui; Takanori Hosokawa; Ken Ueda; Teiji Kuzuya; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Masayuki Kurosaki; Nobuyuki Enomoto; Namiki Izumi
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

5.  Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.

Authors:  S Kobayashi; T Takeda; M Enomoto; A Tamori; N Kawada; D Habu; H Sakaguchi; T Kuroda; K Kioka; S R Kim; T Kanno; T Ueda; M Hirano; S Fujimoto; H Jomura; S Nishiguchi; S Seki
Journal:  Liver Int       Date:  2007-03       Impact factor: 5.828

6.  Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

Authors:  Miharu Hirakawa; Kenji Ikeda; Yasuji Arase; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Hitomi Sezaki; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Hiromitsu Kumada
Journal:  Intern Med       Date:  2008-10-01       Impact factor: 1.271

7.  α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.

Authors:  Yasuhiro Asahina; Kaoru Tsuchiya; Takashi Nishimura; Masaru Muraoka; Yuichiro Suzuki; Nobuharu Tamaki; Yutaka Yasui; Takanori Hosokawa; Ken Ueda; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Masayuki Kurosaki; Nobuyuki Enomoto; Mina Nakagawa; Sei Kakinuma; Mamoru Watanabe; Namiki Izumi
Journal:  Hepatology       Date:  2013-08-19       Impact factor: 17.425

8.  Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.

Authors:  Yuko Nagaoki; Hiroshi Aikata; Norihito Nakano; Fumi Shinohara; Yuki Nakamura; Masahiro Hatooka; Kei Morio; Hiromi Kan; Hatsue Fujino; Tomoki Kobayashi; Takayuki Fukuhara; Keiichi Masaki; Atsushi Ono; Takashi Nakahara; Tomokazu Kawaoka; Daiki Miki; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Shoichi Takahashi; Yoshiiku Kawakami; Hidenori Ochi; Kazuaki Chayama
Journal:  J Gastroenterol Hepatol       Date:  2016-05       Impact factor: 4.029

9.  Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients.

Authors:  Kazumi Yamasaki; Masakuni Tateyama; Seigo Abiru; Atsumasa Komori; Shinya Nagaoka; Akira Saeki; Satoru Hashimoto; Ryu Sasaki; Shigemune Bekki; Yuki Kugiyama; Yuri Miyazoe; Atsushi Kuno; Masaaki Korenaga; Akira Togayachi; Makoto Ocho; Masashi Mizokami; Hisashi Narimatsu; Hiroshi Yatsuhashi
Journal:  Hepatology       Date:  2014-10-02       Impact factor: 17.425

10.  A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.

Authors:  Atsushi Kuno; Yuzuru Ikehara; Yasuhito Tanaka; Kiyoaki Ito; Atsushi Matsuda; Satoru Sekiya; Shuhei Hige; Michiie Sakamoto; Masayoshi Kage; Masashi Mizokami; Hisashi Narimatsu
Journal:  Sci Rep       Date:  2013-01-15       Impact factor: 4.379
View more
  1 in total

1.  Obesity and recurrence-free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C.

Authors:  Hiroji Shinkawa; Shogo Tanaka; Shigekazu Takemura; Tokuji Ito; Takanori Aota; Masaki Koda; Toru Miyazaki; Takatsugu Yamamoto; Shoji Kubo
Journal:  Ann Gastroenterol Surg       Date:  2018-06-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.